Últimos testes

EudraCT Number: 2016-001478-14

Sponsor Protocol Number: 071301

Start Date:

Sponsor Name: Baxalta Innovations GmbH

Full Title: A PROSPECTIVE, PHASE 3, OPEN LABEL, INTERNATIONAL MULTICENTER STUDY ON EFFICACY AND SAFETY OF PROPHYLAXIS WITH rVWF IN SEVERE VON WILLEBRAND DISEASE

Medical condition: Hereditary severe von Willebrand Disease

Disease:	Version	SOC Term	Classification Code	Term	Level
	19.0	10010331 - Congenital, familial and genetic disorders	10047715	Von Willebrand's disease	PT
	19.0	10010331 - Congenital, familial and genetic disorders	10055168	Von Willebrand's factor deficiency	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: GB (Completed) IT (Completed) CZ (Completed) NL (Completed) ES (Completed) DE (Completed) FI (Completed) FR (Completed)

Trial results: View results

EudraCT Number: 2021-000492-36

Sponsor Protocol Number: HOPECOVID-19

Start Date:

Sponsor Name: UCLouvain

Full Title: Home and Outpatients Precocious Eradication of COVID-19

Medical condition: COVID-19

Disease:	Version	SOC Term	Classification Code	Term	Level
	23.0	100000004862	10084382	Coronavirus disease 2019	LLT

Population Age: Adolescents, Under 18, Adults

Gender: Male, Female

Trial protocol: BE (Ongoing)

Trial results: (No results available)

EudraCT Number: 2012-002606-40

Sponsor Protocol Number: CLCZ696B2207

Start Date:

Sponsor Name: Novartis Pharma Service AG

Full Title: A randomized, double-blind, parallel group study to evaluate metabolic effects of LCZ696 and amlodipine in obese hypertensive subjects

Medical condition: Mild to moderate essential hypertension in obese subjects

Disease:	Version	SOC Term	Classification Code	Term	Level
	14.1	10047065 - Vascular disorders	10020772	Hypertension	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Completed) NL (Completed)

Trial results: View results

EudraCT Number: 2012-003012-31

Sponsor Protocol Number: 2011RC23r

Start Date:

Sponsor Name: DIRECTION CENTRALE DU SERVICE DE SANTE DES ARMEES

Full Title: Cardiovascular effects of esmolol alone and in combination with levosimendan during septic shock

Medical condition:

Disease:	Version	SOC Term	Classification Code	Term	Level
	18.0	10021881 - Infections and infestations	10040070	Septic shock	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: FR (Ongoing)

Trial results: (No results available)

EudraCT Number: 2004-000290-58

Sponsor Protocol Number: SP755

Start Date:

Sponsor Name: SCHWARZ BIOSCIENCES GmbH

Full Title: Estudio multicéntrico, doble ciego, aleatorizado, controlado con placebo, en grupos paralelos, para investigar la eficacia y la seguridad de SPM927 (200 mg y 400 mg/día)como tratamiento complementa...

Medical condition: Partial seizures with or without secondary generalization

Disease:

Version

SOC Term

Classification Code

Term

Level

Population Age: Adolescents, Under 18, Adults, Elderly

Gender: Male, Female

Trial protocol: ES (Ongoing)

Trial results: View results

EudraCT Number: 2019-001399-13

Sponsor Protocol Number: 69HCL19_0115

Start Date:

Sponsor Name: Hospices Civils de Lyon

Full Title: MEK and Autophagy Inhibition in Metastatic/Locally Advanced, Unresectable NRAS Melanoma: A Phase Ib/II Trial of Trametinib plus Hydroxychloroquine in Patients with NRAS Melanoma. CHLORO TRAM MEL

Medical condition: Patients with metastatic NRAS melanoma

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	100000004864	10027481	Metastatic melanoma	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: FR (Ongoing)

Trial results: (No results available)

EudraCT Number: 2007-002463-27

Sponsor Protocol Number: LY/AP-01/2007

Start Date:

Sponsor Name: Lybar a.s.

Full Title: Clinical study phase III evaluating the safety of Diffusil H Forte spray.

Medical condition: This is an open-label clinical study evaluating the safety of Diffusil H Forte spray in people with pediculosis or in increased risk of infection of pediculosis.

Disease:	Version	SOC Term	Classification Code	Term	Level
	9.1		10034208	Pediculosis	LLT

Population Age: Children, Adolescents, Under 18, Adults, Elderly

Gender: Male, Female

Trial protocol: CZ (Completed)

Trial results: (No results available)

EudraCT Number: 2019-000845-12

Sponsor Protocol Number: 070219

Start Date:

Sponsor Name: Canisius Wilhelmina Ziekenhuis

Full Title: The effectiveness of vitamin D suppletion on improving symptoms of fatigue in children between 12 and 18 years old

Medical condition: Fatigue

Disease:

Version

SOC Term

Classification Code

Term

Level

Population Age: Adolescents, Under 18

Gender: Male, Female

Trial protocol: NL (Ongoing)

Trial results: (No results available)

EudraCT Number: 2008-003362-26

Sponsor Protocol Number: H552000-0809

Start Date:

Sponsor Name: Almirall Hermal GmbH

Full Title: A phase IIa single-center, randomized, controlled, observer-blind study to investigate the antimicrobial efficacy of topical formulations containing octenidine and prednicarbate in an"expanded flor...

Medical condition: Healthy volunteer trial to investigate whether topical formulations containing Octenidine and Octenidine plus Prednicarbate exert an in vivo antibacterial action on skin surface bacteria multiplied...

Disease:

Version

SOC Term

Classification Code

Term

Level

Population Age: Adults

Gender: Male, Female

Trial protocol: DE (Completed)

Trial results: View results

EudraCT Number: 2005-000051-15

Sponsor Protocol Number: A4061008

Start Date:

Sponsor Name: Pfizer Pharma GmbH

Full Title: Continuing Access to the Tyrosine Kinase Inhibitor of VEGFR-2, AG-013736 (A406) for Patients Previously Receiving AG-013736 in Clinical Trials

Medical condition: Patients who have been treated in previous AG-013736 oncology studies

Disease:

Version

SOC Term

Classification Code

Term

Level

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Completed) CZ (Completed) IT (Completed) HU (Ongoing)

Trial results: (No results available)

Últimos testes

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas